Notification of major interest in shares

RNS Number : 2896O
ConvaTec Group PLC
03 November 2016
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST INSHARESi

 

i

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

 

ConvaTec Group PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

Corrective Filing - See Item 13

 

X

 

3. Full name of person(s) subject to the notification obligation: iii

 

OrbiMed Advisors LLC and OrbiMed Capital LLC

 

4. Full name of shareholder(s)

(if different from 3.):iv

OrbiMed Partners Master Fund Limited OrbiMed Partners II, L.P.

OrbiMed Global Healthcare Master Fund, L.P.

Stichting Depositary APG Developed Markets Equity Pool Worldwide Healthcare Trust PLC

5. Date of the transaction and date on which the threshold is crossed or reached: v

 

October 26, 2016

6. Date on which issuer notified:

 

October 28, 2016

7. Threshold(s) that is/are crossed or reached: vi, vii

 

Not applicable

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

 

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of  voting rights x

Direct

Direct xi

Indire ct xii

Direct

Indirect

 

 

GB00BD3VFW73

 

0

 

0

 

23,000,000

 

23,000,000

 

0

 

1.18%

 

0

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

23,000,000

1.18%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will cease to hold:

 

12. Date on which proxy holder will cease to hold voting rights:

 

 

 

13. Additional information:

 

OrbiMed Advisors LLC and OrbiMed Capital LLC (together, "OrbiMed") are affiliated investment advisers registered with the U.S. Securities and Exchange Commission. OrbiMed acts as investment manager or investment adviser for the funds and accounts listed in Item 4, which beneficially own the shares that are the subject of this notification.

 

This filing (the "New Filing") is being submitted to correct the TR-1 submitted on October 28, 2016 (the "Prior Filing"), as it has been determined that the Prior Filing was filed mistakenly due to a calculation error. The Prior Filing inadvertently identified the 23,000,000 shares referenced in Item 8.A as constituting 3.49% of the voting rights related to the issuer's issued share capital. In fact, the 23,000,000 shares constituted only 1.18% of such voting rights. As a result, no TR-1 filing was actually required, but OrbiMed considers it appropriate to update the market in this way. OrbiMed is submitting the New Filing, with the corrected percentages in the relevant parts of Item 8, to correct the Prior Filing as of the date thereof.

14. Contact name:

Douglas Coon

15. Contact telephone number:

1-212-739-6400

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUGGCGGUPQGAW
UK 100

Latest directors dealings